文献速递血栓与止血白血病

抗凝预防可降低接受天冬酰胺酶为基础治疗的成人急性淋巴细胞白血病患者静脉血栓栓塞发生率

Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
PubMed 文献 · Br J Haematol · 2020-05-12

这项单中心回顾性队列研究纳入214例接受天冬酰胺酶为基础强化化疗的费城染色体阴性成人急性淋巴细胞白血病患者,比较2011至2017年接受低分子量肝素预防的125例与2001至2017年历史对照99例。预防组静脉血栓栓塞发生率为13.6%,对照组为27.3%(OR 0.42,95%CI 0.21-0.83),预防组未记录到大出血。

要点

  • 低分子量肝素预防组VTE发生率13.6%(17/125),历史对照组27.3%(27/99),OR 0.42(95%CI 0.21-0.83)。
  • VTE主要部位包括下肢深静脉血栓54.6%、肺栓塞13.6%和导管相关血栓22.7%。
  • 调整年龄后,T细胞表型ALL与VTE发生相关(OR 3.07,95%CI 1.04-9.08)。

核心结论

  • 低分子量肝素预防可降低接受天冬酰胺酶为基础强化化疗的成人急性淋巴细胞白血病患者症状性静脉血栓栓塞的发生率。

研究设计与样本

  • 单中心回顾性队列研究,纳入2001至2017年接受天冬酰胺酶为基础强化治疗的费城染色体阴性成人急性淋巴细胞白血病患者214例,其中历史对照组99例,预防组125例(预防于2011至2017年给予)。

主要发现

  • 预防组125例中17例(13.6%)在强化治疗阶段发生静脉血栓栓塞,对照组99例中27例(27.3%)发生至少一次血栓事件(OR 0.42,95%CI 0.21-0.83)。
  • 静脉血栓栓塞主要部位包括下肢深静脉血栓54.6%、肺栓塞13.6%和导管相关血栓22.7%。
  • 调整年龄后,T细胞表型ALL与静脉血栓栓塞发生相关(OR 3.07,95%CI 1.04-9.08)。
  • 预防组未记录到大出血。
  • 依诺肝素平均剂量(范围)为0.79(0.39-1.2)mg/kg。

临床怎么用

  • 作者结论认为低分子量肝素预防可降低接受天冬酰胺酶为基础强化化疗的成人急性淋巴细胞白血病患者症状性静脉血栓栓塞的发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a well-known complication in adults receiving asparaginase (ASNase)-based intensification chemotherapy for acute lymphoblastic leukaemia (ALL). The optimal preventative strategy is unclear. Our objective is to determine the effects of low-molecular-weight heparin (LMWH) as primary VTE prophylaxis. A single-centred retrospective cohort study of adult patients with Philadelphia chromosome negative (Ph-) ALL who received ASNase-based intensification from 2001 to 2017, with prophylaxis given from 2011 to 2017. In all, 214 patients were included in this study with 99 in the historical control group and 125 in the prophylaxis group. The mean (range) enoxaparin dose was 0·79 (0·39-1·2) mg/kg. Of the 125 patients in the prophylaxis group 17 (13·6%) developed VTE during the intensification phase, while 27/99 patients (27·3%) in the control cohort experienced at least one thrombotic event (odds ratio [OR] 0·42, 95% confidence interval [CI] 0·21-0·83). Overall, the main sites of VTE incidences included deep vein thrombosis in the lower extremity (54·6%), pulmonary embolism (13·6%) and catheter-related thrombosis (22·7%). In addition, we found that after adjusting for age, T-phenotype ALL was associated with VTE development (OR 3·07, 95% CI 1·04-9·08). There was no documented major bleeding in the prophylaxis group. LMWH prophylaxis reduced the incidence of symptomatic VTE in adult patients with ALL receiving intensification chemotherapy with ASNase.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sibai H, Chen R, Liu X, et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. Br J Haematol. 2020. PMID: 32395867. doi:10.1111/bjh.16695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。